LABA safety studies for asthma saw no increased risk in Advair or Symbicort

After the Serevent Nationwide Surveillance (SNS) and SMART trials both appeared to link the use of long-acting beta agonists (LABAs) to an increased risk of asthma-related death, routine asthma care got scary. The FDA slapped a black box warning on LABAs like Serevent (salmeterol) and Foradil (formoterol) and also the combination treatments containing them (Advair, [… read more]

The post LABA safety studies for asthma saw no increased risk in Advair or Symbicort appeared first on PulmCCM.

Source: PulmCCM

Leave a Reply